Bio-Techne Corporation reported a consolidated net sales increase of 5% for the fiscal year ending June 30, 2025, reaching $1.22 billion, compared to $1.16 billion in the previous fiscal year. The Protein Sciences segment, which constitutes approximately 72% of total sales, generated $870.2 million, reflecting a 5% increase from the prior year. The Diagnostics and Spatial Biology segment also saw growth, with net sales rising 6% to $346.3 million. However, the company experienced a significant decline in net earnings, which fell 56% to $73.4 million, primarily due to a non-recurring arbitration loss, asset impairments, and restructuring charges.
In terms of strategic developments, Bio-Techne completed the acquisition of Lunaphore Technologies SA for $169.7 million in July 2023, enhancing its capabilities in spatial biology solutions. The company also made a $15 million investment in Spear Bio during fiscal 2025 and holds a 19.9% stake in Wilson Wolf Corporation, with plans to acquire the remaining shares by the end of 2027. These acquisitions are part of Bio-Techne's strategy to expand its product offerings and market presence, particularly in high-growth areas such as diagnostics and therapeutics.
Operationally, Bio-Techne employed approximately 3,100 individuals as of June 30, 2025, with a focus on fostering a culture of empowerment and innovation. The company reported no significant customer concentration, as no single customer accounted for more than 10% of sales in either segment. The company also introduced over 400 new products during the fiscal year, indicating a commitment to innovation and product development.
The company’s gross margin decreased to 64.8% in fiscal 2025 from 66.4% in the previous year, influenced by changes in product mix and the reinstatement of incentive accruals. Selling, general, and administrative expenses rose by 26% to $588.5 million, driven by the arbitration award and asset impairments. Despite these challenges, adjusted net earnings increased by 8%, highlighting operational efficiencies within the Protein Sciences segment.
Looking ahead, Bio-Techne anticipates continued growth driven by its strategic acquisitions and product innovations. The company aims to leverage its strong balance sheet to explore new technologies and expand into adjacent markets, while also focusing on enhancing customer experience and operational efficiency. The outlook remains cautiously optimistic, with management emphasizing the importance of navigating market conditions and potential regulatory changes that could impact future performance.
About BIO-TECHNE Corp
Bio-Techne Corporation develops, manufactures, and sells life science reagents, instruments, and diagnostic products for research, diagnostics, and bioprocessing markets worldwide. Its two main segments—Protein Sciences and Diagnostics & Spatial Biology—offer biological reagents, protein analysis tools, molecular diagnostics, and spatial biology solutions. Serving academic, pharmaceutical, biotech, and clinical customers, Bio-Techne leverages innovation, quality manufacturing, and a broad global distribution network to support scientific discovery and disease diagnosis.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.